// App-Quantinova.ai

: Effect of Polypharmacy on Bleeding of Rivaroxaban Versus Vitamin K Antagonist for Treatment of Venous Thromboembolism

Researchers

Presenter

  • I. Bistervels

Principal Investigators

  • M. Gebel

  • A. Lensing

  • S. Middeldorp

  • M. Coppens

Medical Centers

  • Amsterdam UMC, University of Amsterdam, Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands

  • Bayer HealthCare, Wuppertal, Germany

Locations

  • Netherlands

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

Biomarkers

  • Cytochrome P450 Family 3 Subfamily A Member 4

Drug/Treatment

  • rivaroxaban

  • Enoxaparin

  • Enoxaparin sodium

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved